Differential effect of everolimus on progression of early and late cardiac allograft vasculopathy in current clinical practice

American Journal of Transplantation

Volumn 13, Issue 5, 2013, Pages 1217-1226

  Masetti, M ^a   Potena, L ^a   Nardozza, M ^a   Prestinenzi, P ^a   Taglieri, N ^a   Saia, F ^a   Pece, V ^a   Magnani, G ^a   Fallani, F ^a   Coccolo, F ^a   Russo, A ^a   Rapezzi, C ^a   Grigioni, F ^a   Branzi, A ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Cardiac allograft vasculopathy; heart transplantation; immunosuppressive therapy; intravascular ultrasound; risk factors; statins

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; BASILIXIMAB; CYCLOSPORIN; EVEROLIMUS; EZETIMIBE; FLUINDOSTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; STEROID; THYMOCYTE ANTIBODY; TRIACYLGLYCEROL;

ARTERIAL WALL THICKNESS; ARTICLE; CARDIAC ALLOGRAFT VASCULOPATHY; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MEGADOSE; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HEART GRAFT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAVASCULAR ULTRASOUND; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PERIPHERAL EDEMA; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 85027945025     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12208     Document Type: Article

References (32)

1. Stehlik J, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: Twenty-eighth Adult Heart Transplant Report-2011. J Heart Lung Transplant 2011; 30: 1078-1094.
2. Kobashigawa JA., First-year intravascular ultrasound results as a surrogate marker for outcomes after heart transplantation. J Heart Lung Transplant 2003; 22: 711-714.
3. Kobashigawa JA, Tobis JM, Starling RC, et al. Multicenter intravascular ultrasound validation study among heart transplant recipients: Outcomes after five years. J Am Coll Cardiol 2005; 45: 1532-1537.
4. Tuzcu EM, Kapadia SR, Sachar R, et al. Intravascular ultrasound evidence of angiographically silent progression in coronary atherosclerosis predicts long-term morbidity and mortality after cardiac transplantation. J Am Coll Cardiol 2005; 45: 1538-1542.
5. Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333: 621-627.
6. Wenke K, Meiser B, Thiery J, et al. Simvastatin reduces graft vessel disease and morality after heart transplantation. Circulation 1997; 96: 1398-1402.
7. Keogh A, Richardson M, Ruygrok P, et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: A randomized clinical trial. Circulation 2004; 110: 2694-2700.
8. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349: 847-858.
9. Wu H, Ballantyne C, Short B, et al. Statin use and risks of death or fatal rejection in the Heart Transplant Lipid Registry. Am J Cardiol 2004; 95: 367-372.
10. Grigioni F, Carigi S, Potena L, et al. Long-term safety and effectiveness of statins for heart transplant recipients in routine clinical practice. Transplant Proc 2006; 38: 1507-1510.
11. Caforio AL, Tona F, Fortina AB, et al. Immune and nonimmune predictors of cardiac allograft vasculopathy onset and severity: Multivariate risk factor analysis and role of immunosuppression. Am J Transplant 2004; 4: 962-970.
12. Tsutsui H, Ziada KM, Schoenhagen P, et al. Lumen loss in transplant coronary artery disease is a biphasic process involving early intimal thickening and late constrictive remodeling: Results from a 5-year serial intravascular ultrasound study. Circulation 2001; 104: 653-657.
13. Valantine HA., Cardiac allograft vasculopathy: Central role of endothelial injury leading to transplant "atheroma ". Transplantation 2003; 76: 891-899.
14. Mancini D, Pinney S, Burkhoff D, et al. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation 2003; 108: 48-53.
15. Arora S, Ueland T, Wennerblom B, et al. Effect of everolimus introduction on cardiac allograft vasculopathy-Results of a randomized, multicenter trial. Transplantation 2011; 92: 235-243.
16. Potena L, Grigioni F, Magnani G, et al. Prophylaxis versus preemptive anti-cytomegalovirus approach for prevention of allograft vasculopathy in heart transplant recipients. J Heart Lung Transplant 2009; 28: 461-467.
17. Mintz G, Nissen S, Anderson W, et al. ACC clinical expert consensus document on standards for acquisition, measurement and reporting of intravascular ultrasound sudies: A report of the American College of Cardiology task force on Clinical Expert Consensus Documents (Committee to develop a Clinical Expert Consensus Document on standards for acquisition, measurement and reporting of intravascular ultrasound sudies [IVUS]). J Am Coll Cardiol 2001; 37: 1478-1492.
18. Erglis A, Narbute I, Kumsars I, et al. A randomized comparison of paclitaxel-eluting stents versus bare-metal stents for treatment of unprotected left main coronary artery stenosis. J Am Coll Cardiol 2007; 50: 491-497.
19. Potena L, Prestinenzi P, Bianchi IG, et al. Cyclosporine lowering with everolimus versus mycophenolate mofetil in heart transplant recipients: Long-term follow-up of the SHIRAKISS randomized, prospective study. J Heart Lung Transplant 2012; 31: 565-570.
20. Epailly E, Albanell J, Andreassen A, et al. Proliferation signal inhibitors and post-transplant malignancies in heart transplantation: Practical clinical management questions. Clin Transplant 2011; 25: E475-E486.
21. Law MR, Wald NJ, Rudnicka AR., Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: Systematic review and meta-analysis. BMJ 2003; 326: 1423.
22. Magnani G, Carinci V, Magelli C, Potena L, Reggiani LB, Branzi A., Role of statins in the management of dyslipidemia after cardiac transplant: Randomized controlled trial comparing the efficacy and the safety of atorvastatin with pravastatin. J Heart Lung Transplant 2000; 19: 710-715.
23. Potena L, Grigioni F, Ortolani P, et al. Safety and efficacy of early aggressive versus cholesterol-driven lipid-lowering strategies in heart transplantation: A pilot, randomized, intravascular ultrasound study. J Heart Lung Transplant 2011; 30: 1305-1311.
24. Quarta CC, Potena L, Grigioni F, et al. Safety and efficacy of ezetimibe with low doses of simvastatin in heart transplant recipients. J Heart Lung Transplant 2008; 27: 685-688.
25. Mehra MR, Crespo-Leiro MG, Dipchand A, et al. International Society for Heart and Lung Transplantation working formulation of a standardized nomenclature for cardiac allograft vasculopathy-2010. J Heart Lung Transplant 2010; 29: 717-727.
26. Cockcroft D, Gault M., Prediction of creatinine clearance from serum creatinine. Nephron 1975; 16: 31-41.
27. Kobashigawa J, Pauly D, Ross H, et al. Reduction of cardiac allograft vasculopathy with everolimus over mycophenolate mofetil: Intravascular ultrasound results of a randomized multicenter trial. J Heart Lung Transplant 2011; 30: S24-S25.
28. Bouzas-Mosquera A, Crespo-Leiro MG, Paniagua MJ, et al. Adverse effects of mammalian target of rapamycin inhibitors during the postoperative period after cardiac transplantation. Transplant Proc 2008; 40: 3027-3030.
29. Kuppahally S, Al-Khaldi A, Weisshaar D, et al. Wound healing complications with de novo sirolimus versus mycophenolate mofetil-based regimen in cardiac transplant recipients. Am J Transplant 2006; 6: 986-992.
30. Zuckermann A, Arizon JM, Dong G, et al. Impact of de novo everolimus-based immunosuppression on incisional complications in heart transplantation. Transplantation 2011; 92: 594-600.
31. Topilsky Y, Hasin T, Raichlin E, et al. Sirolimus as primary immunosuppression attenuates allograft vasculopathy with improved late survival and decreased cardiac events after cardiac transplantation. Circulation 2012; 125: 708-720.
32. Arora S, Erikstad I, Ueland T, et al. Virtual histology assessment of cardiac allograft vasculopathy following introduction of everolimus-Results of a multicenter trial. Am J Transplant 2012; 12: 2700-2709.